Sarepta Therapeutics, Inc. (SRPT) Stock Rating Reaffirmed by William Blair
Several other research firms have also issued reports on SRPT. Barclays PLC initiated coverage on shares of Sarepta Therapeutics in a report on Wednesday, September 6th. They issued an equal weight rating and a $46.00 price target on the stock. BidaskClub lowered shares of Sarepta Therapeutics from a buy rating to a hold rating in a report on Friday, August 4th. Robert W. Baird reaffirmed an outperform rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, September 6th. Credit Suisse Group lifted their price target on shares of Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an outperform rating in a report on Thursday. Finally, Cowen and Company reissued an outperform rating and set a $69.00 price objective (up from $62.00) on shares of Sarepta Therapeutics in a report on Thursday, July 20th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Sarepta Therapeutics has an average rating of Buy and a consensus price target of $62.31.
Shares of Sarepta Therapeutics (SRPT) opened at 43.01 on Thursday. The firm’s 50-day moving average price is $39.34 and its 200 day moving average price is $34.16. Sarepta Therapeutics has a 52 week low of $25.47 and a 52 week high of $63.73. The stock’s market capitalization is $2.77 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. During the same period in the prior year, the firm posted ($1.19) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics will post ($1.23) earnings per share for the current year.
In other Sarepta Therapeutics news, CFO Sandesh Mahatme sold 50,000 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $2,050,000.00. Following the completion of the transaction, the chief financial officer now owns 41,736 shares in the company, valued at $1,711,176. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Douglas S. Ingram acquired 47,058 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was purchased at an average price of $42.50 per share, with a total value of $1,999,965.00. Following the transaction, the chief executive officer now owns 382,058 shares of the company’s stock, valued at approximately $16,237,465. The disclosure for this purchase can be found here. In the last quarter, insiders sold 78,056 shares of company stock valued at $3,224,208. Insiders own 9.60% of the company’s stock.
Several institutional investors have recently modified their holdings of SRPT. Prentiss Smith & Co. Inc. raised its position in shares of Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 3,166 shares during the period. Ameritas Investment Partners Inc. acquired a new position in shares of Sarepta Therapeutics in the first quarter worth about $127,000. PNC Financial Services Group Inc. raised its position in shares of Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after acquiring an additional 2,800 shares during the period. Cubist Systematic Strategies LLC raised its position in shares of Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after acquiring an additional 2,474 shares during the period. Finally, Edge Wealth Management LLC acquired a new position in shares of Sarepta Therapeutics in the second quarter worth about $175,000. Institutional investors and hedge funds own 65.43% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.